Navigation Links
Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from,Human Clinical Trials for New Cancer Drug

PASADENA, Calif.--(BUSINESS WIRE)--Jun 1, 2007 - Arrowhead Research Corporation (Nasdaq:ARWR) announced today that interim Phase I data has been published in the 2007 American Society for Clinical Oncology Proceedings (ASCO) (Abstract ID 32638). The data are from an ongoing Phase I clinical study designed to evaluate the safety, tolerability, and pharmacokinetics of its lead anti-cancer drug candidate, IT-101, in patients with inoperable or metastatic tumors. IT-101 is a conjugate of the potent anti-cancer drug camptothecin and Insert's proprietary drug delivery technology, Cyclosert(TM).

"The interim IT-101 study results look very promising," stated R. Bruce Stewart, Chairman of Arrowhead. "We were encouraged to see patients who have failed other chemotherapies complete the whole six cycles of treatment without disease progression."

The abstract's authors state that the stable disease rate, although not yet conclusive, is consistent with promising efficacy. In general, IT-101 was well tolerated and pancytopenia was the dose limiting toxicity. Patients that have completed the six cycle treatment regimen and showed stable disease or better are expected to continue to receive treatment on a compassionate care basis. The first person to enter the trial, a pancreatic cancer patient, is stable after 10 months.

"The type of dose limiting toxicity identified is consistent with the expectation for a camptothecin derivative," said Dr. Thomas Schluep, Chief Scientific Officer at Insert. "We are encouraged that, at dose levels that have promising efficacy, we have not seen some of the other deleterious side effects commonly experienced by patients receiving camptothecin class drugs."

Pharmacokinetics data were favorable and consistent with results from preclinical animal studies. In the patients studied, IT-101 showed longer half life, lower clearance and lower volume of distribution than seen in pati
'"/>




Page: 1 2 3

Related medicine technology :

1. Arrowhead Subsidiaries Insert & Calando Present Data on Cyclosert Drug Delivery System at AACR Meeting
2. Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
3. Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
4. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
5. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
6. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
7. The Lancet Publishes PREVAIL Study Results Showing Lovenox Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke
8. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
9. Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
10. Medical Journal Publishes First Large-Scale Survey Revealing Experiences of IPF Patients
11. Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal
Post Your Comments:
(Date:9/17/2014)... BRIC Gynecological Devices Market Outlook to ... new report, "BRIC Gynecological Devices Market Outlook to ... Gynecological Devices market. The report provides value, in ... average prices (in US dollars) within market segments ... and Mechanical Sterilization Devices (Tubal Clips and Rings)), ...
(Date:9/17/2014)... Sept. 17, 2014 The ambulance ... last decade due to the recession, an ... technological advancements. This BCC Research report analyzes ... of the ambulance and emergency medical services ... and hemorrhage control devices, equipment used for ...
(Date:9/17/2014)... YORK , Sept. 17, 2014 Pomerantz ... PDL BioPharma, Inc. ("PDL BioPharma" or the "Company") (NASDAQ: ... S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ... BioPharma and certain of its officers and/or directors have ... Act of 1934.  On September 17, ...
Breaking Medicine Technology:BRIC Gynecological Devices Market Outlook to 2020 2BRIC Gynecological Devices Market Outlook to 2020 3Ambulance and Emergency Equipment: Global Markets 2Ambulance and Emergency Equipment: Global Markets 3Ambulance and Emergency Equipment: Global Markets 4SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PDL BioPharma, Inc. - PDLI 2
(Date:9/17/2014)... Battle Creek, MI (PRWEB) September 17, 2014 ... Recovery , an open-ended drug and alcohol treatment program ... gives them a solid foundation in recovery they can ... and depression. , “About 20% of Americans who are ... or both,” commented A Forever Recovery’s CEO Per ...
(Date:9/17/2014)... has been reserved for the very healthy. Astronauts ... highest physical and psychological standards to prepare them ... of commercial spaceflight, average people can now fly ... very little information about what medical conditions or ... spaceflight environment, as most medical conditions have never ...
(Date:9/17/2014)... In its latest blog post, Best ... having family close by during a stay in rehab can ... is successful, is highlighting a member of the therapeutic care ... of addicts across the country and around the world: dogs. ... the blood pressure, heart rate, and stress levels in recovering ...
(Date:9/17/2014)... 2014 North Central Surgical Center is ... awards for their top-notch services. The hospital was the ... and GYN surgery. , Hospital-wide, North Central was the ... have received this award for two years in a ... percent in the nation for Patient Safety in 2014 ...
(Date:9/17/2014)... WEDNESDAY, Sept. 17, 2014 (HealthDay News) -- A blood ... could provide doctors with a better assessment of the ... If used routinely, this blood test could ... working and actually begins promoting tumor growth, the researchers ... given to patients with advanced prostate cancer and often ...
Breaking Medicine News(10 mins):Health News:Latest A Forever Recovery Blog Post Explores the Link Between Addiction and Depression 2Health News:Latest A Forever Recovery Blog Post Explores the Link Between Addiction and Depression 3Health News:Space: The final frontier… open to the public 2Health News:Latest Best Drug Rehabilitation Blog Post Highlights How Dogs are Helping Addicts Recover 2Health News:North Central Surgical Center Receives Several Accolades 2Health News:DNA Blood Test Might Identify Status of Prostate Cancer 2
... Romania. But now new cases of deaths of birds have been ... in all directions from the Danube Delta. This delta is a ... all the birds that come to Europe. ... infected with bird flu. ,Bird flu is caused by ...
... loss of lung functions may be prevented by Vitamin ... lungs stand to benefit from greater concentrations of the ... breakfast cereals, dairy products and fatty fish. Exposure to ... vitamin D. ,The University of Auckland’s researchers ...
... depot fire accident has been described as an environmental tragedy ... flames are reportedly spewing out a toxic cocktail of chemicals.// ... fuel tank led to the suspension of the firefighting efforts. ... signal had been given. ,As many as 150 ...
... of patients who suffer from Parkinson disease as a ... to a study conducted by the University of Alabama.// ... the levodopa medication for bringing the symptoms under control. ... levodopa medication may result in dyskinesias and motor fluctuations ...
... Scotland figures have revealed that about 34% of the ... or overweight. The Information Statistics Division (ISD) has published ... directly connected to latter year // problems like ... disease, which may prove to be an expensive proposition ...
... increase in demand for Palliative care for treatment of ... Hospitals, which has been reported in the Journal of ... chemotherapy or other treatments no more works, it is ... their suffering. It is found that there is a ...
Cached Medicine News:Health News:Study Says Vitamin D Is Good For Lungs 2Health News:Firefighters Continue To Battle Blaze 2
Provides 30% more magnification and twice the field of view. Adjustable focus, with insufflator bulb....
Features a built-in throat illuminator, providing 30% more magnification and twice the field of view. Adjustable focus....
... The Novus Spectra photocoagulator delivers ... in diode-pumped solid-state (DPSS) technology. Diode ... power from the compact Novus Spectra ... ensures stable beam output and system ...
A standard, durable and reliable indirect....
Medicine Products: